Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 30, Issue 4 SUPPL. 1, 2000, Pages

  Kaplan, J E ^a   Hanson, D ^a   Dworkin, M S ^a   Frederick, T ^a   Bertolli, J ^a   Lindegren, M L ^a   Holmberg, S ^a   Jones, J L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE; PROTEINASE INHIBITOR; RIFABUTIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL INFECTION; CANDIDIASIS; CRYPTOSPORIDIOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; TOXOPLASMOSIS;

EID: 0033803407     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313843     Document Type: Review

References (59)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Update: Trends in AIDS incidence, deaths, and prevalence - United States, 1996
3. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs
4. Changing patterns of mortality across Europe in patients infected with HIV-1
5. Stabilization of in-patient daily census despite continued reduction in HIV-related admissions at a New York City hospital
6. Impact of triple drug therapy on morbidity, mortality, and cost
7. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
8. Spectrum of disease in persons with human immunodeficiency virus infection in the United States
9. Trends in the incidence of outcomes defining acquired immunodeficiency virus syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991
10. Natural history of opportunistic disease in an HIV-infected urban clinical cohort
11. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997
12. Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996
13. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study
14. Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir + ZDV + 3TC to ZDV + 3TC
15. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-1-infected patients treated with highly active antiretroviral therapy
16. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
17. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
18. Can PCP prophylaxis be safely discontinued among clinically improving HIV patients?
19. Discontinuation of PCP prophylaxis is safe in HIV-infected patients after immunologic recovery with HAART: Results of the Gesida 04/98 study
20. 3 after HAART: CIOP study
21. + T-lymphocyte count
22. Gender differences in reported AIDS-indicative diagnoses
23. Frequencies of opportunistic diseases prior to death among HIV-infected persons
24. Human herpesvirus 8 (HHV-8) and Kaposi's sarcoma in persons infected with human immunodeficiency virus
25. Which opportunistic illnesses occur in the era of HAART and at what CD4 cell counts?
26. A randomized placebo-controlled trial of azithromycin prophylaxis for the prevention of Mycobacterium avium complex (MAC) in subjects with increases in CD4 cells on antiretroviral therapy
27. Opportunistic infections (OIs) as emerging infectious diseases: Challenges posed by OIs in the 1990s and beyond
28. Prevalence of HIV infection in the United States, 1984 to 1992
29. A minimum estimate of the number of living HIV infected persons confidentially tested in the United States
30. The care of HIV-infected adults in the United States
31. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United states: Reassessment of indications for chemoprophylaxis
32. Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1)
33. Racial differences in the use of drug therapy for HIV disease in an urban community
34. Correlates of medical service utilization among people with HIV infection
35. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States
36. Variations in the care of HIV-infected adults in the United States
37. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis
38. Prevention Public Health Service task force recommendations for the use of antiretrovirai drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-I transmission in the United States
39. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women
40. On the verge of elimination of perinatally acquired HIV/AIDS? Updated trends in HIV/AIDS in the United States
41. Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the Pediatric Spectrum of Disease Project
42. Guidelines for the use of antiretroviral agents in pediatric HIV infection
43. Centers for Disease Control and Prevention
44. Incidence and predictors of virologic failure to indinavir and/or ritonavir in an urban health clinic
45. Antiretroviral drug resistance testing in adults with HIV infection
46. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
47. Centers for Disease Control and Prevention
48. Continued decline in morbidity and mortality among patients with advanced HIV infection receiving highly active antiretroviral therapy (HAART)
49. Impact of HAART on rates and types of hospitalization at a New York City hospital
50. HAART does not modify HCV replication in HIV-HCV co-infected patients
51. Liver fibrosis progression in patients with hepatitis C and HIV infection
52. Histological damage of hepatitis C in HIV-infected patients
53. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
54. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
55. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
56. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
57. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection
58. Opportunistic infections occurring during highly active antiretroviral treatment
59. Azithromycin (AZM) for M. avium complex (MAC) prophylaxis in HIV patients during the HAART era: Evaluation of a provincial program